HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1′ substituent

HIV-1 protease inhibitors with picomolar potency against PI-resistant HIV-1 by modification of the P1′ substituent HIV protease inhibitors with picomolar potency against PI-Resistant HIV-1 by extension of the P3 substituent Novel HIV-1 protease inhibitors active against multiple PI-Resistant viral strains: coadministration with indinavir P1′ oxadiazole protease inhibitors with excellent activity against native and protease inhibitor-resistant HIV-1 Synthesis of novel HIV protease inhibitors (PI) with activity against PI-resistant virus The design, synthesis and evaluation of novel HIV-1 protease inhibitors with high potency against PI-resistant viral strains Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains Orally bioavailable highly potent HIV protease inhibitors against PI-resistant virus HIV-1 Protease Inhibitors with a Transition-State Mimic Comprising a Tertiary Alcohol: Improved Antiviral Activity in Cells Nonsymmetric P2/P2‘ Cyclic Urea HIV Protease Inhibitors. Structure−Activity Relationship, Bioavailability, and Resistance Profile of Monoindazole-Substituted P2 Analogues